Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The use of long-term non-invasive ventilation (NIV) to treat sleep and breathing disorders in children has increased substantially in the last decade; however, less data exist about its use in infants. Given that infants have distinct sleep and breathing patterns when compared to older children, the outcomes of infants on long-term NIV may differ as well. The aim of this study is to systematically review the use and outcomes of long-term NIV in infants.
Methods: Ovid Medline, Ovid Embase, CINAHL (via EbscoHOST), PubMed, and Wiley Cochrane Library were systematically searched from January 1990 to July 2017. Studies on infants using long-term NIV outside of an acute care setting were included. Data were extracted on study design, population characteristics, and NIV outcomes.
Results: A total of 327 studies were full-text reviewed, with final inclusion of 60. Studies were distributed across airway (40%), neuromuscular (28%), central nervous system (10%), cardio-respiratory (2%), and multiple (20%) disease categories. Of the 18 airway studies reporting on NIV outcomes, 13 (72%) reported improvements in respiratory parameters. Of the 12 neuromuscular studies exclusively on spinal muscular atrophy type 1 (SMA1), six (50%) reported decreased hospitalizations and nine (75%) reported on mortality outcomes. Risk of bias was moderate to serious, and quality of the evidence was low to very low for all studies. Most studies had an observational design with no control group, limiting the potential for a meta-analysis.
Conclusion: The outcomes reported in studies differed by the disease category being studied. Studies on airway conditions showed improvements in respiratory parameters for infants using NIV. Studies on neuromuscular disorder, which were almost exclusively on SMA1, reported decreased hospitalizations and prolonged survival. Overall, it appears that NIV is an effective long-term therapy for infants. However, the high risk of bias and low quality of the available evidence limited strong conclusions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816035 | PMC |
| http://dx.doi.org/10.3389/fped.2018.00013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The deadly drink: Nipah virus transmission through date palm sap, cultural practices and the evolution of behavioral interventions in Bangladesh over two decades.
J Infect Public Health
August 2025
Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh; Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, UK. Electronic address:
Nipah virus (NiV) has emerged as a significant public health threat, with recurring outbreaks in Bangladesh often linked to the consumption of raw date palm sap contaminated by fruit bats (Pteropus species). Over the past two decades, substantial efforts have been made to understand the cultural context of sap consumption, promoting behavior change and developing interventions to prevent NiV spillover. Despite these efforts, achieving sustainable change in sap consumption practices remains challenging due to deep-seated cultural practices, community perceptions of sap consumption, habitual behaviors, limited awareness of health risks and economic barriers.
View Article and Find Full Text PDFNocturnal hypoventilation in children with obesity.
Sleep Med
October 2025
Semmelweis University Pediatric Center, MTA Center of Excellence, Bókay János street 53-54, 1083, Budapest, Hungary. Electronic address:
Study Objectives: Sleep-disordered breathing (SDB) is an increasingly recognized co-morbidity in childhood obesity. SDB may contribute to the excessive weight gain; however, diagnosis and treatment strategies are not well-defined during childhood. Most pediatric studies focus solely on obstructive sleep apnea (OSA), although hypoventilation may play a separate but pivotal role in the course of the condition.
View Article and Find Full Text PDF[Home mechanical ventilation: What's new?].
Dtsch Med Wochenschr
August 2025
Klinik für Pneumologie, Beatmungsmedizin und thorakale Onkologie, Lungenklinik Köln-Merheim, Kliniken der Stadt Köln gGmbH, Universität Witten-Herdecke, Köln, Germany.
Home mechanical ventilation (HMV) has evolved significantly over the past decade. While initially used primarily for neuromuscular diseases, the increasing application of non-invasive ventilation (NIV) for chronic obstructive pulmonary disease (COPD) has demonstrated significant benefits in reducing mortality and hospitalizations. Concurrently, the prevalence of obesity hypoventilation syndrome (OHS) is rising, necessitating adapted treatment strategies.
View Article and Find Full Text PDFRespiratory management of critically ill pneumocystis pneumonia patients: a multicenter retrospective study.
Ann Intensive Care
August 2025
Department of Infectious Diseases, INSERM, University Hospital of Nantes and Centre d'Investigation Clinique 1413, Nantes, France.
Background: Pneumocystis jirovecii pneumonia (PjP) is a rising cause of acute respiratory failure in immunocompromised patients, often requiring Intensive Care Unit (ICU) admission. However, optimal ventilatory strategies remain unclear.
Methods: For the present study, we conducted an ancillary analysis of the PRONOCYSTIS study, a large multicenter cohort of PjP patients.
Role of Non-Invasive Ventilation in Elderly Patients: Therapeutic Opportunity or Medical Futility? An Updated Narrative Review.
Medicina (Kaunas)
July 2025
Respiratory Medicine Unit, Department of Medicine, Azienda Ospedaliera Universitaria Integrata of Verona, University of Verona, 37126 Verona, Italy.
: Acute respiratory failure (ARF) represents an increasingly relevant clinical challenge in older subjects due to population aging and the high prevalence of cardiopulmonary comorbidities. Non-invasive ventilation (NIV), developed as continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP), has become a first-line treatment in various forms of ARF, including acute cardiogenic pulmonary oedema (ACPE) and acute exacerbations of COPD (AECOPD), offering several clinical advantages. In this context, the limited evidence on the efficacy of NIV in older patients leaves considerable uncertainty as to whether it constitutes a valid therapeutic option or represents medical futility in these patients.
View Article and Find Full Text PDF